The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
Abstract
Cancer cells frequently harbor defects in DNA repair pathways, leading to genomic instability. This can foster tumorigenesis but also provides a weakness in the tumor that can be exploited therapeutically. Tumors with compromised ability to repair double-strand DNA breaks by homologous recombination, including those with defects in BRCA1 and BRCA2, are highly sensitive to blockade of the repair of DNA single-strand breaks via the inhibition of the enzyme poly(ADP) ribose polymerase. This provides the basis for a novel synthetic lethal approach to cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Self-citationSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Self-citationAssociation of BRCA1 with Rad51 in Mitotic and Meiotic Cells
Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., & Livingston, D. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81847-4 · Cited by 1,459
Amé, J., Spenlehauer, C., & de Murcia, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,459
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
Self-citationBrca1 Controls Homology-Directed DNA Repair
Moynahan, M. E., Chiu, J. W., Koller, B. H., & Jasin, M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80202-6 · Cited by 1,245
Takata, M., Sasaki, M. S., Sonoda, E., Morrison, C., Hashimoto, M., Utsumi, H., Yamaguchi‐Iwai, Y., Shinohara, A., & Takeda, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.18.5497 · Cited by 1,229
Chromosomal stability and the DNA double-stranded break connection
van Gent, D. C., Hoeijmakers, J. H. J., & Kanaar, R. (2001) · Nature Reviews Genetics · doi:10.1038/35056049 · Cited by 1,219
Pathways of DNA Double-Strand Break Repair during the Mammalian Cell Cycle
Rothkamm, K., Krüger, I., Thompson, L. H., & Lübrich, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.16.5706-5715.2003 · Cited by 1,189
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Self-citationBRCA2 Is Required for Homology-Directed Repair of Chromosomal Breaks
Moynahan, M. E., Pierce, A. J., & Jasin, M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00174-5 · Cited by 1,006
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg050 · Cited by 970
Xu, X., Weaver, Z., Linke, S. P., Li, C., Gotay, J., Wang, X.-W., Harris, C. C., Ried, T., & Deng, C.-X. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80466-9 · Cited by 819
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W., & Friend, S. H. (1997) · Science · doi:10.1126/science.278.5340.1064 · Cited by 773
Identification of a RING protein that can interact in vivo with the BRCA1 gene product
Wu, L. C., Wang, Z. W., Tsan, J. T., Spillman, M. A., Phung, A., Xu, X. L., Yang, M.-C. W., Hwang, L.-Y., Bowcock, A. M., & Baer, R. (1996) · Nature Genetics · doi:10.1038/ng1296-430 · Cited by 746
BRCA2 Function in DNA Binding and Recombination from a BRCA2-DSS1-ssDNA Structure
Yang, H., Jeffrey, P. D., Miller, J., Kinnucan, E., Sun, Y., Thomä, N. H., Zheng, N., Chen, P.-L., Lee, W.-H., & Pavletich, N. P. (2002) · Science · doi:10.1126/science.297.5588.1837 · Cited by 705
Chambon, P., Weill, J. D., & Mandel, P. (1963) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(63)90024-x · Cited by 654
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
Goggins, M., Schutte, M. E. M., Lü, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., Yeo, C. J., Jackson, C. E., Lynch, H. T., Hruban, R. H., et al. (1996) · PubMed · Cited by 642
Involvement of Brca2 in DNA Repair
Patel, K. J., Yu, V. P. C. C., Lee, H., Corcoran, A., Thistlethwaite, F. C., Evans, M. J., Colledge, W. H., Friedman, L. S., Ponder, B. A. J., & Venkitaraman, A. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80035-0 · Cited by 634
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
Gudmundsdottir, K., & Ashworth, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209874 · Cited by 622
Self-citationWooster, R., & Weber, B. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra012284 · Cited by 605
PARP is important for genomic stability but dispensable in apoptosis
Wang, Z.-Q., Stingl, L., Morrison, C., Jantsch, M., Los, M., Schulze-Osthoff, K., & Wagner, E. F. (1997) · Genes & Development · doi:10.1101/gad.11.18.2347 · Cited by 557
Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors
Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S. V., Mathew, C. G., Joenje, H., Mok, S. C., & D'Andrea, A. D. (2003) · Nature Medicine · doi:10.1038/nm852 · Cited by 536
Genetic Steps of Mammalian Homologous Repair with Distinct Mutagenic Consequences
Stark, J. M., Pierce, A. J., Oh, J., Pastink, A., & Jasin, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9305-9316.2004 · Cited by 501
Basal-like breast cancer and the BRCA1 phenotype
Turner, N. C., & Reis-Filho, J. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209876 · Cited by 478
BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.
Yuan, S. F., Lee, S. Y., Chen, G., Song, M., Tomlinson, G. E., & Lee, E. Y.-H. P. (1999) · PubMed · Cited by 474
Improved survival in women with BRCA‐associated ovarian carcinoma
Cass, I., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A., & Karlan, B. Y. (2003) · Cancer · doi:10.1002/cncr.11310 · Cited by 433
Tutt, A. (2001) · The EMBO Journal · doi:10.1093/emboj/20.17.4704 · Cited by 429
Dobzhansky, T. (1946) · Genetics · doi:10.1093/genetics/31.3.269 · Cited by 427
EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer
Hughes-Davies, L., Huntsman, D., Ruas, M., Fuks, F., Bye, J., Chin, S.-F., Milner, J., Brown, L. A., Hsu, F., Gilks, B., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00930-9 · Cited by 421
DNA recombination: the replication connection
Haber, J. E. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(99)01413-9 · Cited by 411
Arnaudeau, C., Lundin, C., & Helleday, T. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4564 · Cited by 386
Shen, S.-X., Weaver, Z., Xu, X., Li, C., Weinstein, M., Chen, L., Guan, X.-Y., Ried, T., & Deng, C.-X. (1998) · Oncogene · doi:10.1038/sj.onc.1202243 · Cited by 329
Yu, V. P. C. C., Koehler, M., Steinlein, C., Schmid, M., Hanakahi, L. A., van Gool, A. J., West, S. C., & Venkitaraman, A. R. (2000) · Genes & Development · doi:10.1101/gad.14.11.1400 · Cited by 320
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology
Ratnam, K., & Low, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2260 · Cited by 286
Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2
Esashi, F., Galkin, V. E., Yu, X., Egelman, E. H., & West, S. C. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1245 · Cited by 280
In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs)
Otto, H., Reche, P. A., Bazan, F., Dittmar, K., Haag, F., & Koch-Nolte, F. (2005) · BMC Genomics · doi:10.1186/1471-2164-6-139 · Cited by 259
Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein
Lomonosov, M., Anand, S., Sangrithi, M., Davies, R., & Venkitaraman, A. R. (2003) · Genes & Development · doi:10.1101/gad.279003 · Cited by 256
Kraakman-van der Zwet, M., Overkamp, W. J. I., van Lange, R. E. E., Essers, J., van Duijn-Goedhart, A., Wiggers, I., Swaminathan, S., van Buul, P. P. W., Errami, A., Tan, R. T. L., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.2.669-679.2002 · Cited by 254
Utilizing RNA interference to enhance cancer drug discovery
Iorns, E., Lord, C. J., Turner, N., & Ashworth, A. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2355 · Cited by 251
Self-citationInteraction with the BRCA2 C terminus protects RAD51–DNA filaments from disassembly by BRC repeats
Davies, O. R., & Pellegrini, L. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1251 · Cited by 225
TUTT, A. N. J., LORD, C. J., MCCABE, N., FARMER, H., TURNER, N., MARTIN, N. M., JACKSON, S. P., SMITH, G. C. M., & ASHWORTH, A. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.012 · Cited by 196
Self-citationChromosomal Translocation Mechanisms at Intronic Alu Elements in Mammalian Cells
Elliott, B., Richardson, C., & Jasin, M. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.028 · Cited by 177
Global synthetic-lethality analysis and yeast functional profiling
Ooi, S. L., Pan, X., Peyser, B. D., Ye, P., Meluh, P. B., Yuan, D. S., Irizarry, R. A., Bader, J. S., Spencer, F. A., & Boeke, J. D. (2006) · Trends in Genetics · doi:10.1016/j.tig.2005.11.003 · Cited by 164
Truncated BRCA2 is cytoplasmic: Implications for cancer-linked mutations
Spain, B. H., Larson, C. J., Shihabuddin, L. S., Gage, F. H., & Verma, I. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.13920 · Cited by 161
Ataxia telangiectasia gene mutations in leukaemia and lymphoma
Boultwood, J. (2001) · Journal of Clinical Pathology · doi:10.1136/jcp.54.7.512 · Cited by 153
Mutator pathways unleashed by epigenetic silencing in human cancer
Jacinto, F. V., & Esteller, M. (2007) · Mutagenesis · doi:10.1093/mutage/gem009 · Cited by 151
McCabe, N., Lord, C. J., Tutt, A. N. J., Martin, N. M. B., Smith, G. C. M., & Ashworth, A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.9.2141 · Cited by 148
Self-citationBoulton, S. J., Kyle, S., & Durkacz, B. W. (1999) · Carcinogenesis · doi:10.1093/carcin/20.2.199 · Cited by 121
Inhibition of poly(ADP-ribose) polymerase in cancer
Plummer, E. R. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.02.004 · Cited by 106
Loh, V. M. J., Cockcroft, X. F., Dillon, K. J., Dixon, L., Drzewiecki, J., Eversley, P. J., Gomez, S., Hoare, J., Kerrigan, F., Matthews, I. T. W., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.03.026 · Cited by 94
Structure and function of the double-strand break repair machinery.
Shin, D. S., Chahwan, C., Huffman, J., & Tainer, J. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.022 · Cited by 76
Gallmeier, E., & Kern, S. E. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.1909 · Cited by 69
Improved survival in BRCA2 carriers with ovarian cancer
Pal, T., Permuth‐Wey, J., Kapoor, R., Cantor, A. B., & Sutphen, R. (2006) · Familial Cancer · doi:10.1007/s10689-006-9112-x · Cited by 67
Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery
Noël, G., Giocanti, N., Fernet, M., Mégnin-Chanet, F., & Favaudon, V. (2003) · BMC Cell Biology · doi:10.1186/1471-2121-4-7 · Cited by 66
RAD51, BRCA2 and DNA repair: a partial resolution
Lord, C. J., & Ashworth, A. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb0607-461 · Cited by 62
Self-citationSymington, L. S. (2005) · EMBO Reports · doi:10.1038/sj.embor.7400438 · Cited by 24
Cited by
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Self-citationAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Hoeijmakers, J. H. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804615 · Cited by 2,239
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,518
Metadata
- Authors
- Ashworth, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-08-01
- Volume
- 26
- Issue
- 22
- Pages
- 3785-3790
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2002962154
- Cited by
- 856
- References
- 63
- FWCI
- 25.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.